CD274 and neoplasm: The assessment of PD-L1 protein expression on tumor cells has limited power for selecting patients as a biomarker due to intra-tumoral heterogeneity, inter-tumoral heterogeneity, differences in PD-L1 staining, and the impact of treatment [17].